Bristol Myer OTC Stock Target Price and Analyst Consensus

BMYMP
 Stock
  

USD 1,190  10.00  0.83%   

Analysts of Bristol Myer Squi render investment recommendations by dissecting financials, analyzing earning calls, and talking to Bristol Myer vendors, executives, and customers to validate their buy-or-sell advice. Unfortunately, the analyst consensus on Bristol Myer is currently unavailable. Please use our comprehensive buy-or-sell advice module to check the latest Macroaxis investment opinion on Bristol Myer
  

About Bristol Myer Target Price Projections

Bristol Myer's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to otc stocks such as Bristol Myer Squi and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the OTC Stock is worth and where the price will be in a year from now. Generally, the target price of Bristol depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Bristol Myer Squi including its fundamental analysis.

Additional Bristol Myer Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any OTC Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Bristol Myer is a key component of Bristol Myer valuation and have some predictive power on the future returns of a Bristol Myer.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bristol Myer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bristol Myer in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
1,1881,1901,192
Details
Intrinsic
Valuation
LowReal ValueHigh
1,0021,0041,309
Details
Naive
Forecast
LowNext ValueHigh
1,2101,2121,214
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1,1661,1941,222
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bristol Myer. Your research has to be compared to or analyzed against Bristol Myer's peers to derive any actionable benefits. When done correctly, Bristol Myer's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bristol Myer Squi.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested over 90 shares
Outsourcing
Invested over 90 shares
Continue to Macroaxis Advice on Bristol Myer to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
The data published in Bristol Myer's official financial statements usually reflect Bristol Myer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol Myer Squi. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myer's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bristol Myer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myer Squi. Please utilize our Beneish M Score to check the likelihood of Bristol Myer's management to manipulate its earnings.